Global Pulmonary Arterial Hypertension (2020 to 2025) - by Drug Class, Route of Administration, Distribution Mode and Geography
Technology Advancements such as Biomaker and New Gene Therapy for the Treatment Segments Covered Based on Drug Class, the pulmonary arterial hypertension (PAH) market has been segmented into Soluble Guanylate Cyclase (SGC) stimulators, prostacyclin and prostacyclin analogs, phosphodiesterase 5 (PDE-5), and Endothelin Receptor Antagonists (ERA). ERA And Prostacyclin And Prostacyclin Analogs for treating PAH have the largest market share owing to the significant increase in the sales of this drug for the treatment of pulmonary arterial hypertension. Based on Distribution Mode, Online Pharmacies...
Source: prnewswire.com